Schrodinger (NASDAQ:SDGR) Insider Sells $928,062.63 in Stock

Schrodinger, Inc. (NASDAQ:SDGR) insider Karen Akinsanya sold 31,599 shares of Schrodinger stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $29.37, for a total transaction of $928,062.63. Following the sale, the insider owned 69,956 shares of the company’s stock, valued at approximately $2,054,607.72. This trade represents a 31.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Schrodinger Stock Up 4.2%

Shares of NASDAQ:SDGR traded up $1.22 during trading on Monday, reaching $30.24. The stock had a trading volume of 2,887,620 shares, compared to its average volume of 1,403,211. The business has a fifty day moving average price of $18.51 and a 200-day moving average price of $15.20. The stock has a market cap of $2.23 billion, a P/E ratio of -40.86 and a beta of 1.69. Schrodinger, Inc. has a fifty-two week low of $10.94 and a fifty-two week high of $31.03.

Schrodinger (NASDAQ:SDGR) last announced its earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.49. The firm had revenue of $58.89 million for the quarter, compared to analyst estimates of $47.19 million. Schrodinger had a negative net margin of 20.98% and a negative return on equity of 16.37%. Schrodinger’s revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.65) earnings per share. As a group, equities analysts forecast that Schrodinger, Inc. will post -1.5 EPS for the current year.

Hedge Funds Weigh In On Schrodinger

Several institutional investors and hedge funds have recently bought and sold shares of SDGR. BlackRock Inc. acquired a new position in shares of Schrodinger in the 2nd quarter valued at $170,978,000. Rubric Capital Management LP increased its holdings in shares of Schrodinger by 43.8% during the 1st quarter. Rubric Capital Management LP now owns 6,000,000 shares of the company’s stock worth $68,160,000 after buying an additional 1,828,502 shares during the last quarter. Amova Asset Management Americas Inc. increased its holdings in shares of Schrodinger by 6.8% during the 4th quarter. Amova Asset Management Americas Inc. now owns 2,819,670 shares of the company’s stock worth $50,359,000 after buying an additional 180,735 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Schrodinger in the 2nd quarter worth $4,986,000. Finally, Tejara Capital Ltd purchased a new position in shares of Schrodinger in the 2nd quarter worth $4,553,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on SDGR. Wall Street Zen upgraded Schrodinger from a “strong sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings upgraded Schrodinger from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Finally, UBS Group initiated coverage on Schrodinger in a research report on Friday, August 14th. They set a “neutral” rating and a $19.00 target price on the stock. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $20.50.

Schrodinger Company Profile

Schrödinger, Inc develops computational software designed to accelerate drug discovery and materials science research. Its platform uses physics-based modeling, machine learning and related computational methods to help scientists analyze molecular structures, predict interactions and identify potential compounds for further development.

The company’s software products support a range of research activities, including molecular modeling, virtual screening, structure-based drug design, free-energy calculations and collaborative data management.